Table 4

Best tumor response per RECIST v.1.1 in evaluable patients* who had at least one postbaseline disease assessment†

Pacmilimab+ipilimumab dose (mg/kg), n (%)All
(N=27)
0.3+3
(n=6)
1+3
(n=3)
3+3
(n=3)
10+3
(n=8)
10+6/10+10
(n=7)
Overall response rate1 (17)1 (33)1 (33)1 (13)1 (14)5 (19)
95% CI 6 to 38
 Complete response1 (17)00001 (4)
 Partial response01 (33)1 (33)1 (13)1 (14)4 (15)
 Stable disease01 (33)03 (38)1 (14)5 (19)
 Progressive disease4 (67)1 (33)1 (33)2 (25)3 (43)11 (41)
Disease control rate‡1 (17)2 (67)1 (33)4 (50)2 (29)10 (37)
95% CI 19 to 58
  • *The efficacy evaluable population includes treated patients who had an adequate baseline disease assessment (N=27).

  • †Six patients did not have a qualifying post-baseline disease assessment: Five patients discontinued prior to the first tumor assessment. One patient discontinued due to symptom deterioration. This patient had a tumor assessment, but it took place <4 weeks after the baseline assessment.

  • ‡Disease control rate (includes patients with complete response, partial response, or stable disease).

  • RECIST, Response Evaluation Criteria in Solid Tumors.